Eli Lilly and Company (NYSE:LLY) is Rowlandmiller & PARTNERS.ADV’s 4th Largest Position

Rowlandmiller & PARTNERS.ADV lessened its holdings in Eli Lilly and Company (NYSE:LLY) by 0.3% during the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 20,619 shares of the company’s stock after selling 70 shares during the quarter. Eli Lilly and Company comprises 3.7% of Rowlandmiller & PARTNERS.ADV’s portfolio, making the stock its 4th largest position. Rowlandmiller & PARTNERS.ADV’s holdings in Eli Lilly and Company were worth $18,267,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in LLY. International Assets Investment Management LLC lifted its stake in shares of Eli Lilly and Company by 87,091.7% in the third quarter. International Assets Investment Management LLC now owns 12,463,182 shares of the company’s stock worth $11,041,631,000 after buying an additional 12,448,888 shares in the last quarter. Swedbank AB purchased a new position in Eli Lilly and Company in the 1st quarter worth approximately $932,797,000. Vanguard Group Inc. lifted its position in Eli Lilly and Company by 1.6% in the 1st quarter. Vanguard Group Inc. now owns 72,745,011 shares of the company’s stock valued at $56,592,709,000 after acquiring an additional 1,133,810 shares in the last quarter. Wulff Hansen & CO. boosted its stake in Eli Lilly and Company by 90,438.0% during the 2nd quarter. Wulff Hansen & CO. now owns 937,068 shares of the company’s stock valued at $848,403,000 after purchasing an additional 936,033 shares during the last quarter. Finally, GQG Partners LLC increased its holdings in shares of Eli Lilly and Company by 20.2% in the 1st quarter. GQG Partners LLC now owns 3,848,886 shares of the company’s stock worth $2,994,280,000 after purchasing an additional 648,094 shares in the last quarter. Institutional investors own 82.53% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on LLY shares. Berenberg Bank increased their price objective on Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the company a “buy” rating in a research report on Wednesday, August 14th. Sanford C. Bernstein started coverage on shares of Eli Lilly and Company in a research note on Thursday, October 17th. They issued an “outperform” rating and a $1,100.00 price target for the company. Evercore ISI upgraded shares of Eli Lilly and Company to a “hold” rating in a research report on Thursday, September 5th. Morgan Stanley reiterated an “overweight” rating and set a $1,106.00 target price on shares of Eli Lilly and Company in a research note on Tuesday, August 27th. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $885.00 price target on shares of Eli Lilly and Company in a research note on Monday, September 16th. Three investment analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $1,013.41.

Eli Lilly and Company Trading Up 0.1 %

Eli Lilly and Company stock opened at $892.51 on Friday. Eli Lilly and Company has a 12-month low of $547.61 and a 12-month high of $972.53. The firm has a market capitalization of $848.27 billion, a price-to-earnings ratio of 109.92, a P/E/G ratio of 3.24 and a beta of 0.42. The firm has a 50 day moving average of $920.32 and a 200 day moving average of $860.96. The company has a current ratio of 1.11, a quick ratio of 0.87 and a debt-to-equity ratio of 1.74.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Thursday, August 8th. The company reported $3.92 EPS for the quarter, beating the consensus estimate of $2.64 by $1.28. Eli Lilly and Company had a net margin of 18.86% and a return on equity of 67.52%. The firm had revenue of $11.30 billion for the quarter, compared to the consensus estimate of $9.83 billion. As a group, research analysts predict that Eli Lilly and Company will post 14.05 earnings per share for the current year.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.